Literature DB >> 30851550

Evaluating vaccination strategies for tuberculosis in endemic and non-endemic settings.

Marissa Renardy1, Denise E Kirschner2.   

Abstract

According to the World Health Organization, tuberculosis (TB) is the leading cause of death from infectious disease worldwide (WHO, 2017). While there is no effective vaccine against adult pulmonary TB, more than a dozen vaccine candidates are in the clinical trial pipeline. These include both pre-exposure vaccines to prevent initial infections and post-exposure vaccines to prevent reactivation of latent disease. Many epidemiological models have been used to study TB, but most have not included a continuous age structure and the possibility of both pre- and post-exposure vaccination. Incorporating age-dependent death rates, disease properties, and social contact data allows for more realistic modeling of disease spread. We propose a continuous age-structured model for the epidemiology of tuberculosis with pre- and post-exposure vaccination. We use uncertainty and sensitivity analysis to make predictions about the efficacy of different vaccination strategies in a non-endemic setting (United States) and an endemic setting (Cambodia). In particular, we determine optimal age groups to target for pre-exposure and post-exposure vaccination in both settings. We find that the optimal age groups tend to be younger for Cambodia than for the US, and that post-exposure vaccination has a significantly larger effect than pre-exposure vaccination in the US.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Age-structured; Epidemiology; Mycobacterium tuberculosis; Vaccination

Mesh:

Year:  2019        PMID: 30851550      PMCID: PMC6447051          DOI: 10.1016/j.jtbi.2019.02.020

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  43 in total

1.  United States life tables, 2000.

Authors:  Elizabeth Arias
Journal:  Natl Vital Stat Rep       Date:  2002-12-19

Review 2.  The success and failure of BCG - implications for a novel tuberculosis vaccine.

Authors:  Peter Andersen; T Mark Doherty
Journal:  Nat Rev Microbiol       Date:  2005-08       Impact factor: 60.633

3.  What is the outcome of targeted tuberculosis screening based on universal genotyping and location?

Authors:  Patrick K Moonan; Joseph Oppong; Behzad Sahbazian; Karan P Singh; Raghbir Sandhu; Gerry Drewyer; Terry Lafon; Marco Marruffo; Teresa N Quitugua; Charles Wallace; Stephen E Weis
Journal:  Am J Respir Crit Care Med       Date:  2006-05-25       Impact factor: 21.405

Review 4.  Potential impact of tuberculosis vaccines as epidemic control agents.

Authors:  T Lietman; S M Blower
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

5.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents.

Authors:  Jacco Wallinga; Peter Teunis; Mirjam Kretzschmar
Journal:  Am J Epidemiol       Date:  2006-09-12       Impact factor: 4.897

7.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

Review 8.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

Authors:  Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye
Journal:  Arch Intern Med       Date:  2003-05-12

9.  Tuberculous meningitis and miliary tuberculosis in young children.

Authors:  F van den Bos; M Terken; L Ypma; J L L Kimpen; E D Nel; H S Schaaf; J F Schoeman; P R Donald
Journal:  Trop Med Int Health       Date:  2004-02       Impact factor: 2.622

Review 10.  Potential public health impact of new tuberculosis vaccines.

Authors:  Elad Ziv; Charles L Daley; Sally Blower
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883

View more
  3 in total

1.  Structural identifiability analysis of age-structured PDE epidemic models.

Authors:  Marissa Renardy; Denise Kirschner; Marisa Eisenberg
Journal:  J Math Biol       Date:  2022-01-04       Impact factor: 2.259

Review 2.  Clinical Development of New TB Vaccines: Recent Advances and Next Steps.

Authors:  Mark Hatherill; Richard G White; Thomas R Hawn
Journal:  Front Microbiol       Date:  2020-01-30       Impact factor: 5.640

3.  Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India.

Authors:  Rebecca C Harris; Matthew Quaife; Chathika Weerasuriya; Gabriela B Gomez; Tom Sumner; Fiammetta Bozzani; Richard G White
Journal:  Nat Commun       Date:  2022-02-01       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.